Study guide

4.5 Hematology, Anemia Evaluation, Transfusion Medicine, & Common Cancers

Medical Council of Canada Qualifying Examination Part I MCCQE Part I

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, Blueprint & Canadian Medical Practice

1.1 MCCQE Part I Format, Scoring (439 Scale), & Strategy 1.2 The MCC Blueprint Matrix: Dimensions of Care & Physician Activities 1.3 Canadian Healthcare System, CanMEDS Roles, & Interprofessional Care 1.4 Evidence-Based Medicine, Study Design, & Clinical Statistics

2 Chapter 2: Population Health, Health Promotion & Preventive Care

2.1 Canadian Task Force on Preventive Health Care (CTFPHC) Screening Guidelines 2.2 Immunization Schedules (NACI) & Vaccine-Preventable Diseases across Lifespan 2.3 Disease Prevention, Lifestyle Counselling, & Harm Reduction 2.4 Outbreak Management, Disease Surveillance, & Infection Control 2.5 Occupational, Environmental, & Travel Medicine in Canada

3 Chapter 3: Internal Medicine — Cardiovascular & Respiratory Systems

3.1 Hypertension Canada 2020/2025 Guidelines, Dyslipidemia, & Primary Prevention 3.2 Ischemic Heart Disease, Acute Coronary Syndromes, & Heart Failure Management 3.3 Arrhythmias, Valvular Heart Disease, & Infective Endocarditis 3.4 Asthma, COPD, & Respiratory Failure (CTS Guidelines) 3.5 Thromboembolic Disease (DVT/PE), Pneumonia, & Pleural Effusions

4 Chapter 4: Internal Medicine — GI, Endocrine, Renal & Hematology/Oncology

4.1 Gastrointestinal Disorders, Acute Abdomen, & Liver/Biliary Disease 4.2 Diabetes Canada 2020/2025 Guidelines & Glycemic Management 4.3 Thyroid, Adrenal, Pituitary, & Electrolyte Disturbances 4.4 Acute Kidney Injury (AKI), Chronic Kidney Disease (CKD), & Nephrology 4.5 Hematology, Anemia Evaluation, Transfusion Medicine, & Common Cancers

5 Chapter 5: General Surgery, Orthopedics, & Emergency Care

5.1 Surgical Evaluation, Preoperative Clearance, & Postoperative Complications 5.2 Trauma Management (ATLS Protocol) & Burns 5.3 Acute Surgical Conditions (Appendicitis, Cholecystitis, Bowel Obstruction) 5.4 Fractures, Dislocations, Joint Pain, & Musculoskeletal Emergencies 5.5 Vascular Emergencies, Wound Care, & Shock Recognition

6 Chapter 6: Pediatrics & Adolescent Health

6.1 Pediatric Growth, Developmental Milestones, & Well-Child Examinations 6.2 Neonatal Resuscitation, Jaundice, & Common Congenital Anomalies 6.3 Pediatric Respiratory Emergencies (Croup, Bronchiolitis, Asthma) 6.4 Common Pediatric Infections, Exanthems, & Fever of Unknown Origin 6.5 Pediatric Abdominal Pain, Dehydration, & Fluid Management

7 Chapter 7: Obstetrics & Gynecology

7.1 Routine Antepartum Care, Screening, & Prenatal Diagnosis (SOGC Guidelines) 7.2 Medical Complications of Pregnancy (Preeclampsia, Gestational Diabetes, Infections) 7.3 Labor, Intrapartum Management, & Postpartum Complications/Hemorrhage 7.4 Abnormal Uterine Bleeding, Gynecologic Infections, & Contraception/Menopause 7.5 Gynecologic Oncology & Pelvic Mass Evaluation

8 Chapter 8: Psychiatry & Mental Health

8.1 Mood Disorders (Depression, Bipolar) & Suicide Risk Assessment 8.2 Anxiety Disorders, OCD, PTSD, & Somatic Symptom Disorders 8.3 Psychotic Disorders & Schizophrenia Management 8.4 Substance Use Disorders, Withdrawal Syndromes, & Harm Reduction 8.5 Pediatric, Perinatal, & Geriatric Psychiatry (Cognitive Impairment / Delirium)

9 Chapter 9: Neurology, Rheumatology, & Dermatology

9.1 Acute Stroke, TIA, & Neurovascular Emergencies 9.2 Headaches, Seizures, Movement Disorders, & Neuromuscular Disease 9.3 Inflammatory Arthritides (RA, Gout, SpA) & Systemic Autoimmune Diseases (SLE, Vasculitis) 9.4 Common Dermatologic Conditions, Cutaneous Manifestations of Systemic Disease, & Skin Cancers 9.5 Musculoskeletal Soft Tissue Injuries, Back Pain, & Physical Medicine

10 Chapter 10: Legal, Ethical, & Professional Behaviours in Canadian Practice

10.1 Informed Consent, Capacity Assessment, & Substitute Decision-Making (CMPA) 10.2 Medical Confidentiality, Privacy Laws (PIPEDA/PHIPA), & Disclosure of Harm 10.3 CMA Code of Ethics, Professionalism, & Physician Health/Boundary Issues 10.4 Mandatory Reporting (Child/Elder Abuse, Driving Safety, Fitness to Practice) & Quality/Safety

4.5 Hematology, Anemia Evaluation, Transfusion Medicine, & Common Cancers

Key Takeaways Explain This Topic AI

Microcytic anemia evaluation relies on serum ferritin (ferritin < 30 µg/L is diagnostic of Iron Deficiency Anemia); newly diagnosed IDA in men or postmenopausal women requires endoscopic evaluation to rule out GI malignancy.

Macrocytic anemia with hypersegmented neutrophils indicates megaloblastic etiology; Vitamin B12 deficiency causes subacute combined degeneration with elevated MMA and homocysteine, whereas folate deficiency elevates homocysteine alone.

Canadian Blood Services (CBS) transfusion guidelines recommend a restrictive RBC transfusion threshold of Hb < 70 g/L for stable patients (target Hb 70–80 g/L; target Hb ≥ 80–90 g/L in active acute coronary syndrome).

Transfusion-Related Acute Lung Injury (TRALI) is distinguished from Transfusion-Associated Circulatory Overload (TACO) by normal/low BP, normal JVP, normal BNP, and lack of response to diuretics.

Febrile neutropenia (ANC < 0.5 x 10^9/L with fever ≥ 38.3°C) is a medical emergency requiring immediate empiric broad-spectrum IV antipseudomonal monotherapy (piperacillin-tazobactam) within 1 hour.

Last updated: July 2026

  • 4.5 Hematology, Anemia Evaluation, Transfusion Medicine, & Common Cancers
  • Algorithmic Evaluation of Anemia by MCV

Anemia is defined as hemoglobin < 130 g/L in adult males and < 120 g/L in non-pregnant adult females. Initial evaluation categorizes anemia by Mean Corpuscular Volume (MCV) .

1. Microcytic Anemia (MCV < 80 fL) - Differential Mnemonic: TAILS

Iron Deficiency Anemia (IDA) : Most common cause worldwide. Serum ferritin < 30 µg/L is the single most sensitive and specific diagnostic marker. Further labs: Low serum iron, high TIBC, low transferrin saturation (< 20%). Peripheral film shows microcytic hypochromic RBCs and pencil cells.

Mandatory Clinical Rule : Any adult male or postmenopausal female with newly diagnosed IDA requires endoscopic evaluation ( Colonoscopy + Gastroscopy ) to rule out occult gastrointestinal malignancy (e.g., cecal adenocarcinoma).

Anemia of Chronic Disease / Inflammation (ACD) : Driven by elevated hepcidin , which sequesters iron in macrophages. Serum ferritin is normal or elevated (acute phase reactant), low TIBC, low serum iron.

Thalassemia Trait (Alpha or Beta) : Microcytosis out of proportion to mild anemia. Mentzer Index (MCV / RBC count) < 13 strongly points to Thalassemia trait (Index > 13 points to IDA). Confirmed via hemoglobin electrophoresis (elevated HbA2 > 3.5% in Beta-thalassemia trait).

Lead Poisoning : Basophilic stippling on peripheral film, ringed sideroblasts in marrow.

2. Normocytic Anemia (MCV 80 – 100 fL)

Evaluate the Reticulocyte Production Index (RPI) :

Hyperproliferative (RPI > 2%) : Indicates intact marrow response to Hemolysis or acute blood loss. Hemolytic markers: Elevated LDH, decreased haptoglobin, elevated indirect bilirubin, spherocytes or schistocytes.

Direct Antiglobulin Test (DAT / Coombs Test) : Positive = Autoimmune Hemolytic Anemia (AIHA) (Warm IgG vs Cold IgM); Negative = Non-immune hemolysis (G6PD deficiency, Hereditary Spherocytosis, PNH).

Hypoproliferative (RPI < 2%) : Bone marrow failure/suppression, early iron deficiency, Chronic Kidney Disease (erythropoietin deficiency), hypothyroidism.

3. Macrocytic Anemia (MCV > 100 fL)

Inspect peripheral blood film for hypersegmented neutrophils (≥ 5% of neutrophils with ≥ 5 lobes or 1 neutrophil with ≥ 6 lobes):

Megaloblastic Anemia (Hypersegmented neutrophils present -> Impaired DNA synthesis):

Vitamin B12 (Cobalamin) Deficiency : Pernicious anemia (anti-intrinsic factor antibodies), ileal resection, strict vegan diet. Clinical features: Macrocytic anemia PLUS neurological deficits (Subacute Combined Degeneration of spinal cord: loss of vibration/proprioception, spastic paraparesis). Labs: Elevated Methylmalonic Acid (MMA) AND elevated Homocysteine .

Folate Deficiency : Alcohol use disorder, malnutrition, methotrexate. Clinical features: Macrocytic anemia WITHOUT neurological deficits . Labs: Elevated Homocysteine ONLY; Normal MMA .

Non-Megaloblastic Macrocytosis (No hypersegmented neutrophils): Alcohol use disorder, chronic liver disease, hypothyroidism, reticulocytosis, Myelodysplastic Syndrome (MDS).

  • Bleeding Disorders & Coagulation Cascade Interpretation
  • Primary vs Secondary Hemostasis
  • Parameter Primary Hemostasis Disorders Secondary Hemostasis Disorders
  • Primary Defect Platelets or vessel wall defect Coagulation factor deficiency or inhibitor

Bleeding Pattern Mucosal bleeding (epistaxis, menorrhagia, gingival), petechiae, purpura Deep tissue hematomas, hemarthrosis (joint bleeding), delayed surgical bleeding

Screening Tests Platelet count, Bleeding Time / PFA-100 Prothrombin Time (PT/INR), Activated Partial Thromboplastin Time (aPTT)

Prototype Conditions vWD, ITP, TTP, DIC, Aspirin/Clopidogrel Hemophilia A (Factor VIII), Hemophilia B (Factor IX), Warfarin, Vitamin K deficiency

Key Hemostatic Pathologies

von Willebrand Disease (vWD) : Most common inherited bleeding disorder (Autosomal Dominant). vWF mediates platelet adhesion and carries Factor VIII. Screening: Normal platelet count, prolonged bleeding time, prolonged or normal aPTT , normal PT. Treatment: Desmopressin (DDAVP) (releases stored vWF from Weibel-Palade bodies) for mild type 1 vWD; vWF/Factor VIII concentrate for severe cases.

Hemophilia A & B : X-linked recessive factor deficiencies (Factor VIII = Hemophilia A; Factor IX = Hemophilia B). Features: Isolated prolonged aPTT , normal PT, normal platelets. 1:1 Mixing Study corrects aPTT. Treatment: Recombinant Factor VIII or IX replacement.

Disseminated Intravascular Coagulation (DIC) : Widespread microvascular thrombosis with consumptive coagulopathy. Causes: Sepsis, trauma, obstetric catastrophes, APL. Labs: Thrombocytopenia, prolonged PT/INR and aPTT, low fibrinogen (<1.5 g/L), elevated D-dimer , and schistocytes.

  • Transfusion Medicine & Canadian Blood Services (CBS) Guidelines
  • Restrictive RBC Transfusion Strategy

Canadian Blood Services and Choosing Wisely Canada recommend a restrictive transfusion threshold of Hb < 70 g/L for hemodynamically stable adult inpatient populations, transfusing 1 unit of RBCs at a time to maintain a target Hb of 70–80 g/L. Exception : In patients with active Acute Coronary Syndrome (ACS) or symptomatic myocardial ischemia, maintain a target Hb threshold of ≥ 80–90 g/L .

Acute Transfusion Reactions Comparison

Reaction Type Pathophysiology Key Clinical Features Management

Acute Hemolytic (AHTR) ABO incompatibility Fever, flank pain, hypotension, hemoglobinuria, DIC STOP transfusion , IV normal saline, maintain urine output

TRALI Donor anti-HLA antibodies -> neutrophil activation in lungs Non-cardiogenic edema , hypoxia, Normal/Low BP , bilateral infiltrates within 6h STOP transfusion , oxygen, mechanical ventilation ( Do NOT give diuretics )

TACO Volume overload from rapid transfusion Cardiogenic edema , hypoxia, Elevated BP , elevated JVP, elevated BNP STOP transfusion , oxygen, IV Furosemide (diuresis)

Febrile Non-Hemolytic Cytokines accumulated in stored blood Mild fever (>1°C rise), chills, no hemolysis or hypoxia STOP transfusion to rule out hemolysis; Antipyretics; Leukoreduction

Anaphylaxis Recipient anti-IgA antibodies reacting against donor IgA Sudden bronchospasm, stridor, hypotension, urticaria STOP transfusion , IM Epinephrine , IV fluids, washed RBCs in future

  • Oncologic Emergencies & Common Malignancies
  • Febrile Neutropenia

Defined as a single oral temperature ≥ 38.3°C (or ≥ 38.0°C sustained over 1 hour) PLUS an Absolute Neutrophil Count (ANC) < 0.5 x 10^9/L (or ANC < 1.0 x 10^9/L with expected drop to < 0.5 x 10^9/L).

Emergency Management : Medical emergency! Obtain 2 sets of blood cultures (peripheral + central line). Initiate empiric broad-spectrum IV antipseudomonal monotherapy within 1 hour of presentation. First-line agent: Piperacillin-tazobactam (Tazocin) 4.5 g IV q6h (or Cefepime 2 g IV q8h, or Meropenem 1 g IV q8h). Do NOT delay antibiotic administration for diagnostic imaging or laboratory results!

Tumor Lysis Syndrome (TLS)

Massive destruction of rapidly proliferating malignant cells (e.g., Burkitt lymphoma, ALL) post-chemotherapy.

Laboratory Triad : Hyperuricemia, Hyperkalemia, Hyperphosphatemia, with Secondary Hypocalcemia .

Prevention & Treatment : Aggressive IV hydration (2–3 L/m²/day). Rasburicase (recombinant urate oxidase) for high risk; Allopurinol for low-to-moderate risk.

Multiple Myeloma

Plasma cell dyscrasia secreting monoclonal immunoglobulin (M-spike on SPEP).

CRAB Criteria :

C : Calcium elevated (> 2.75 mmol/L).

R : Renal insufficiency (creatinine > 177 µmol/L due to light chain cast nephropathy).

A : Anemia (normocytic normochromic, Hb < 100 g/L).

B : Bone lesions (lytic punched-out lesions on skeletal survey, pathologic fractures).

Diagnostic Markers: Rouleaux formation on blood film, elevated ESR (>100 mm/h), Bence Jones proteinuria (UPEP), >10% clonal plasma cells on bone marrow biopsy.

Warning

MCCQE1 High-Yield Distinction: TRALI vs TACO Acute respiratory distress occurring within 6 hours of blood transfusion:

• TRALI : Non-cardiogenic, Normal or Low BP , Normal JVP, Normal BNP. Treatment: Oxygen & Mechanical Ventilation ( Do NOT give diuretics! ).

• TACO : Cardiogenic volume overload, Elevated/High BP , Elevated JVP, Elevated BNP. Treatment: Oxygen & IV Furosemide .

Loading diagram... Algorithmic Evaluation of Anemia Based on MCV and Reticulocyte Production Index